izpis_h1_title_alt

Multiple omics levels of chronic lymphocytic leukemia
ID Turk, Aleksander (Avtor), ID Čeh, Eva (Avtor), ID Calin, George Adrian (Avtor), ID Kunej, Tanja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,66 MB)
MD5: 1811DA7A7934367F0F43AE44B0CE5AA4
URLURL - Izvorni URL, za dostop obiščite https://www.nature.com/articles/s41420-024-02068-2#Sec7 Povezava se odpre v novem oknu

Izvleček
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the proliferation of functionally mature but incompetent B cells. It is the most prevalent type of leukemia in Western populations, accounting for approximately 25% of new leukemia cases. While recent advances, such as ibrutinib and venetoclax treatment have improved patient outlook, aggressive forms of CLL such as Richter transformation still pose a significant challenge. This discrepancy may be due to the heterogeneity of factors contributing to CLL development at multiple -omics levels. However, information on the omics of CLL is fragmented, hindering multi-omics-based research into potential treatment options. To address this, we aggregated and presented a selection of important aspects of various omics levels of the disease in this review. The purpose of the present literature analysis is to portray examples of CLL studies from different omics levels, including genomics, epigenomics, transcriptomics, epitranscriptomics, proteomics, epiproteomics, metabolomics, glycomics and lipidomics, as well as those identified by multi-omics approaches. The review includes the list of 102 CLL-associated genes with relevant genomics information. While single-omics studies yield substantial and useful data, they omit a significant level of complex biological interplay present in the disease. As multi-omics studies integrate several different layers of data, they may be better suited for complex diseases such as CLL and have thus far yielded promising results. Future multi-omics studies may assist clinicians in improved treatment choices based on CLL subtypes as well as allow the identification of novel biomarkers and targets for treatments.

Jezik:Angleški jezik
Ključne besede:genetics, genomics, omics, medicine, chronic lymphocytic leukemia
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:BF - Biotehniška fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:14 str.
Številčenje:Vol. 10, art. 293
PID:20.500.12556/RUL-159636 Povezava se odpre v novem oknu
UDK:575:616
ISSN pri članku:2058-7716
DOI:10.1038/s41420-024-02068-2 Povezava se odpre v novem oknu
COBISS.SI-ID:199666947 Povezava se odpre v novem oknu
Datum objave v RUL:17.07.2024
Število ogledov:272
Število prenosov:32
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cell death discovery
Založnik:Nature Publishing Group
ISSN:2058-7716
COBISS.SI-ID:284185344 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:genetika, genomika, omike, medicina, kronična limfocitna levkemija

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P4-0220
Naslov:Primerjalna genomika in genomska biodiverziteta

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj